Pentamidine
Nebupent, Pentam, Pentamidine Isethionate (pentamidine) is a small molecule pharmaceutical. Pentamidine was first approved as Pentam on 1984-10-16. It is used to treat pneumocystis pneumonia, protozoan infections, trypanosomiasis, and visceral leishmaniasis in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| respiratory tract diseases | D012140 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| nebupent | New Drug Application | 2024-10-15 |
| pentam 300 | New Drug Application | 2022-09-13 |
| pentamidine isethionate | ANDA | 2025-10-31 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J2545 | Pentamidine isethionate, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per 300 mg |
| J7676 | Pentamidine isethionate, inhalation solution, compounded product, administered through dme, unit dose form, per 300 mg |
| S0080 | Injection, pentamidine isethionate, 300 mg |
| S9061 | Home administration of aerosolized drug therapy (e.g., pentamidine); administrative services, professional pharmacy services, care coordination, all necessary supplies and equipment (drugs and nursing visits coded separately), per diem |
Clinical
Clinical Trials
47 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pneumocystis pneumonia | D011020 | EFO_0007448 | B59 | 3 | 1 | 7 | 2 | 12 | 25 |
| Pneumonia | D011014 | EFO_0003106 | J18 | 2 | 1 | 1 | 2 | 11 | 17 |
| Infections | D007239 | EFO_0000544 | — | 1 | — | 1 | 1 | 1 | 4 |
| Pneumocystis infections | D016720 | EFO_0007447 | — | — | — | — | 1 | 1 | 2 |
| Pneumocystis | D011010 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 2 | 1 | 8 | — | 11 | 22 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 1 | — | 8 | — | 2 | 11 |
| Leishmaniasis | D007896 | EFO_0005044 | B55 | — | 4 | 3 | — | 1 | 7 |
| Aids-related opportunistic infections | D017088 | — | — | — | — | 5 | — | 1 | 6 |
| Cutaneous leishmaniasis | D016773 | — | B55.1 | — | 3 | 1 | — | 1 | 4 |
| Lymphoma | D008223 | — | C85.9 | 1 | 1 | 1 | — | — | 3 |
| Respiratory aspiration | D053120 | EFO_1001839 | — | — | — | 2 | — | 1 | 3 |
| Visceral leishmaniasis | D007898 | — | B55.0 | — | — | 2 | — | — | 2 |
| Hodgkin disease | D006689 | — | C81 | 1 | — | 1 | — | — | 2 |
| Aids-related complex | D000386 | EFO_0007137 | B20 | — | — | 2 | — | — | 2 |
Show 6 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | — | — | 1 | 2 | — | — | — | 2 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 2 | 2 | — | — | — | 2 |
| Kidney transplantation | D016030 | — | — | 2 | 2 | — | — | — | 2 |
| Colonic neoplasms | D003110 | — | C18 | 1 | 1 | — | — | — | 1 |
| Renal insufficiency | D051437 | — | N19 | 1 | 1 | — | — | — | 1 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 1 | — | — | — | 1 |
| Hypertrophic cicatrix | D017439 | — | L91.0 | 1 | 1 | — | — | — | 1 |
| Hypertrophy | D006984 | EFO_0002460 | — | 1 | 1 | — | — | — | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | — | — | — | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 1 | — | — | — | 1 |
Show 3 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Fatty liver | D005234 | EFO_0003934 | — | 1 | — | — | — | — | 1 |
| Alcoholic fatty liver | D005235 | — | K70.0 | 1 | — | — | — | — | 1 |
| Carcinoma | D002277 | — | C80.0 | 1 | — | — | — | — | 1 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 1 | — | — | — | — | 1 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hematologic neoplasms | D019337 | — | — | — | — | — | — | 1 | 1 |
| Neoplasms | D009369 | — | C80 | — | — | — | — | 1 | 1 |
| Communicable diseases | D003141 | — | — | — | — | — | — | 1 | 1 |
| Drug evaluation | D004341 | — | — | — | — | — | — | 1 | 1 |
| Treatment adherence and compliance | D000074822 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Pentamidine |
| INN | pentamidine |
| Description | Pentamidine is a diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease. It has a role as a trypanocidal drug, an antifungal agent, a NMDA receptor antagonist, an anti-inflammatory agent, a chemokine receptor 5 antagonist, an EC 2.3.1.48 (histone acetyltransferase) inhibitor, a calmodulin antagonist, a S100 calcium-binding protein B inhibitor and a xenobiotic. It is a carboxamidine, a diether and an aromatic ether. It is a conjugate base of a pentamidinium(2+). |
| Classification | Small molecule |
| Drug class | pentamidine derivatives/analogues |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N=C(N)c1ccc(OCCCCCOc2ccc(C(=N)N)cc2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 100-33-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL55 |
| ChEBI ID | 45081 |
| PubChem CID | 4735 |
| DrugBank | DB00738 |
| UNII ID | 673LC5J4LQ (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 8,066 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,038 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use